• Sonuç bulunamadı

TAVR, NOACs, NAFLD, and a Happy New Year

N/A
N/A
Protected

Academic year: 2021

Share "TAVR, NOACs, NAFLD, and a Happy New Year"

Copied!
1
0
0

Yükleniyor.... (view fulltext now)

Tam metin

(1)

Editorial

TAVR, NOACs, NAFLD, and a Happy New Year

1

I am pleased to present a very important review, “The implications and requirements of transcatheter aortic valve replacement in low-risk patients,” by E. Murat Tuzcu and Ahmad Edris, from Cleveland Clinic, Abu Dhabi. This article provides important details related to this procedure.

I am also very happy to offer another very valuable review, “Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillation,” by Anetta Undas and Leszek Drabik, from Poland. As the editor-in-chief of the Polish Heart Journal, Anetta Undas kindly submitted this review to our journal as part of the effort to encourage scientific collaboration among national journals of the European Society of Cardiology. The authors describe chal-lenges in the use of NOACs in cancer patients with atrial fibrillation and summarized current expert opinions on the subject.

Aslan et al., from Turkey, investigated the effects of melatonin on the protection provided by ischemic postconditioning in ischemia reperfusion-induced infarct size and the roles of uncoupling protein 3, irisin, and nuclear factor-kappa B levels.

“In-stent restenosis of drug-eluting stents in patients with diabetes mellitus: Clinical pre-sentation, angiographic features and outcomes,” reported by Paramasivam et al., from India, provides a useful comparison for patients who do not have diabetes mellitus.

Gao et al., from China, describe the effects of losartan, a selective angiotensin II type 1 receptor (AT1R) blocker, on the electrophysiological changes induced by stretch in atrial my-ocytes associated with blocking of the AT1 receptor, and a beneficial effect in the treatment of atrial fibrillation.

“Assessment of left ventricular function in type 2 diabetes mellitus patients with non-alco-holic fatty liver disease using three-dimensional speckle tracking echocardiography,” by Dong et al., from China, provides very timely details on this condition.

As always, we have several interesting case reports, e-page originals, etc.

I wish our readers a very happy new year with this first issue of our journal for 2020. Prof. Dr. Çetin Erol

Editor-in-Chief Ankara-Turkey

©Copyright 2020 by Turkish Society of Cardiology - Available online at www.anatoljcardiol.com DOI:10.14744/AnatolJCardiol.2020.1

Address for Correspondence: Prof. Dr. Çetin Erol, Ankara Üniversitesi Tıp Fakültesi, İbn-i Sina Hastanesi, Kardiyoloji Anabilim Dalı, Ankara, Türkiye

Referanslar

Benzer Belgeler

Despite these limitations, we believe that our results are meaningful because it is the first study evaluating the incidence of stroke or systemic embolic events and major

Non-vitamin K antagonist oral anticoagulants (NOACs), or direct oral anticoagulants, are approved for treatment of stroke prevention in patients with nonvalvular atrial

The patient remained under observation in the infectious disease department and intensive care unit for 25 days... was provided and the patient was discharged

An analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibitor Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial

In addition, it has been found that serum ghrelin levels in patients with chronic heart failure were significantly lower than those in the control group, and ghrelin levels varied

Therefore, monitoring the anticoagulant effects of NOAC is important in this subset of an- ticoagulated patients; the need for anticoagulation at high body weights is considered

In their study, the authors re- ported that warfarin-treated patients had higher levels of self- reported symptoms of depression and anxiety and compromised health-related quality

I have read with great interest the article entitled “Compari- son of health-related quality of life among patients using novel oral anticoagulants or warfarin for non-valvular